Shedding light on KIF1A associated neurological disorder (KAND)
KIF1A Associated Neurological Disorder (KAND) is a very rare genetic condition that affects the brain and nervous system.
It is caused by a mutation in the KIF1A gene, discovered in the early 2010s, a gene that normally helps nerve cells transport essential materials. When this gene does not work properly, nerve cells struggle to communicate, which can lead to difficulties with movement, balance, vision, learning, or speech.
Around 30 to 40% of diagnosed individuals also experience seizures. Even though KAND is not visible from the outside, it has a major impact on daily life and independence.
A rare disorder with a unique story
Doctors began noticing signs of KAND in the early 2000s, when children showed unusual combinations of neurological symptoms that did not match any known condition.
For many years, families received incomplete or incorrect diagnoses because the true cause remained unknown. A turning point came in 2011, when researchers linked mutations in the KIF1A gene to these symptoms. This discovery revealed that KAND is a spectrum disorder, meaning symptoms can range from mild to severe depending on the specific mutation.
It also explained why many cases appear in families with no history of neurological disease, since most mutations occur spontaneously.
KAND around the world
KAND is extremely rare. As of 2024, fewer than 500 cases have been formally diagnosed worldwide, although experts believe the real number is higher because many children remain undiagnosed or misdiagnosed.
Most children receive a diagnosis between infancy and age five, often after years of medical testing. The rise of genetic testing, especially whole‑exome sequencing since the mid‑2010s, has helped doctors identify KAND earlier and more accurately.
As awareness grows, more families are finally getting answers after long diagnostic journeys.
Living with KAND : care and daily challenges
There is currently no cure for KAND. Care focuses on helping each person stay as mobile, comfortable, and independent as possible.
Many children benefit from regular physical, occupational, and speech therapy to support development and daily activities. Some need help managing seizures, vision problems, or muscle stiffness.
Families often adapt their homes to make daily life safer and easier as needs change. These approaches do not stop the progression of the condition, but they improve comfort, communication, and quality of life.
Progress and hope in research
Research on KAND has grown rapidly since the discovery of the KIF1A gene’s role in 2011. Scientists are now studying how different mutations affect nerve cells and why symptoms vary so widely.
Several research teams are exploring new treatment possibilities, including gene‑based therapies, drugs that could protect nerve cells, and approaches aimed at slowing the progression of the disease. While these treatments are still in early stages, each new discovery brings hope for better care and future therapies.
The importance of awareness
KAND is still widely unknown, even though the first KIF1A gene mutations were linked to the disorder in 2011 and the term KAND began to be used in the mid‑2010s. Today, in 2024, only a few hundred people worldwide have a confirmed diagnosis, and many families spend several years sometimes more than five searching for answers before KAND is finally identified.
Raising awareness helps shorten this long and stressful journey, encourages earlier genetic testing, and supports research efforts that have been growing steadily over the past decade. The more people, doctors, and institutions learn about KAND, the more understanding, resources, and support families can receive.
Sources
